d from still higher-margin prescription drugs targeting Crohn's disease (Remicade), cancer (Zytig a, Velcade), schizophrenia (Risperdal), diabetes (Invokana), psoriasis (Stela ra), migraines (Topamax), heart disease (Xarelto) and attention deficit disorder (Concerta). As of the start of this summer the c